On April 9, Alcon debuted as an independent, publicly traded company as it completed its separation from Novartis. The company’s shares begin trading yesterday on the SIX Swiss Exchange and New York Stock Exchange (NYSE) under the symbol “ALC.” Alcon is one of the largest eyecare device companies in the world, with complementary businesses in Surgical and Vision Care. The company has a global presence in 74 countries and serves patients in more than 140, with fast-growing businesses in emerging markets. According to a news release from the company, Alcon has a wide array of eyecare offerings in the industry with products that can treat eye disorders at each stage of life. “For more than 70 years, Alcon has been dedicated to helping people see brilliantly and now, as an independent company, we are pursuing even more opportunities to further that mission,” said David Endicott, CEO of Alcon. Read More.